Teladoc Company Profile (NYSE:TDOC)

Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc, Inc. (NYSE:TDOC) released its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.02. The company earned $44.60 million during the quarter, compared to analysts' expectations of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company's revenue was up 68.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.38) EPS. View Teladoc's Earnings History.

Teladoc is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Teladoc.

Teladoc issued an update on its FY17 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of ($1.55)-($1.52) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.99). The company issued revenue guidance of $230-$235 million, compared to the consensus revenue estimate of $232.27 million.Teladoc also updated its Q3 guidance to ($0.58)-($0.56) EPS.

11 analysts have issued 1-year target prices for Teladoc's stock. Their predictions range from $27.00 to $42.00. On average, they anticipate Teladoc's stock price to reach $37.60 in the next year. View Analyst Ratings for Teladoc.

Here are some recent quotes from research analysts about Teladoc stock:

• 1. According to Zacks Investment Research, "Teladoc’s stock has outperformed the industry year to date. The company is seeing a steady growth in its business with insurers and customers increasingly embracing telehealth. The company also made some effort to grow inorganically a with a number of acquisitions made since its inception, which has expanded its distribution capabilities and broadened its service offering. The company is a leader in its sector and boasts of big clients. Its strong guidance for 2017 instills optimism. Nevertheless, Teladoc has incurred significant losses from past many years. Also, Teladoc has been unable to generate cash from operations and we have doubts over its ability to do so in the coming quarters." (9/21/2017)
• 2. Cantor Fitzgerald analysts commented, "Strategy makes sense. Boston-based Best Doctors is a medical consultation company focused on second opinions. Its primary customer base lines up nicely with that of TDOC in that it offers cost-containment solutions to employers and payer/provider solutions. In addition to offering expert medical reviews, it provides potential physician referrals to members. With Best Doctors, TDOC expands its range of services into higher-acuity (costs) healthcare delivery. Strategically, the combination of Best Doctors and TDOC makes sense to us. Financials are a different story. TDOC indicates that Best Doctors is expected to generate revenue in excess of $100 million in 2017. This compares with Best Doctors’ 2016 revenue of $92 million (net of divestitures). Our standalone TDOC revenue estimate is $182.5 million for 2017. On an annualized basis, Best Doctors generates about $8.8 million of adjusted EBITDA. TDOC’s 2017 adjusted EBITDA guidance prior to the acquisition was a loss of $19.5-22.5 million. Although Best Doctors should be immediately additive to TDOC’s adjusted EBITDA, added interest expense and more shares outstanding will likely result in a slightly higher loss per share in 2018, before any revenue and cost synergies. Before synergies, the EV/EBITDA valuation for Best Doctors is about 50x (on a run-rate basis), which is expensive." (6/19/2017)
• 3. Cowen and Company analysts commented, "We are positive on TDOC's partnership with Accolade as it should help drive utilization for members entitled to both benefits. For clients with the combined offering, it has demonstrated improvements in utilization, with mgmt noting ~30% higher utilization. The partnership is already embedded into 2017 guidance, which gives us incremental comfort in the implied utilization ramp." (3/16/2017)
• 4. Chardan Capital analysts commented, "After market close on Wed., TDOC reported earnings with a beat and a mixed guide for 2017. For 4Q16, Teladoc beat the Street consensus by 2% on the topline and by $0.04 on the bottom line. Management guided to topline growth in 2017 of 48%, in-line with Street consensus and re-affirmed its target of being adj. EBITDA breakeven in 4Q17. Management also guided to more EBITDA loss in 2017 than the Street expected in the first 3 quarters driven by various investments in growth. We adjust our estimates down slightly and in-line with Management Guidance for 2017. We raise our PT to $28 based on multiple expansion we see in 2017 as TDOC's operating characteristics improve relative to valuation comps and investor confidence grows in the company's execution." (3/2/2017)

Some companies that are related to Teladoc include ICU Medical (ICUI), Molina Healthcare (MOH), Cantel Medical Corp. (CMD), Patterson Companies (PDCO), Nektar Therapeutics (NKTR), Mallinckrodt PLC (MNK), BeiGene (BGNE), LivaNova PLC (LIVN), Insulet Corporation (PODD), Evotec AG (EVTCY), Agios Pharmaceuticals (AGIO), Hutchison China MediTech Limited (HCM), Portola Pharmaceuticals (PTLA), Chemed Corp. (CHE), Penumbra (PEN), AveXis (AVXS), Sarepta Therapeutics (SRPT) and HealthEquity (HQY).

Teladoc's management team includes the folowing people:

• David B. Snow Jr., Independent Chairman of the Board
• Jason Gorevic, President, Chief Executive Officer, Director
• Mark J. Hirschhorn, Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Peter N. Nieves, Executive Vice President, Chief Revenue Officer
• Gabriel R. Cappucci, Senior Vice President, Chief Accounting Officer, Controller
• Michael H. King, Chief Sales Officer
• Adam C. Vandervoort, Chief Legal Officer and Secretary
• Helen Darling, Independent Director
• William H. Frist M.D., Independent Director
• Michael S. Goldstein CPA, Independent Director

(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Capital World Investors (7.50%), Tiger Global Management LLC (7.22%), BlackRock Inc. (7.02%), Vanguard Group Inc. (5.55%) and Alliancebernstein L.P. (5.10%). Company insiders that own Teladoc stock include Adam C Vandervoort, Dana G Jr Mead, James K Outland, Jason N Gorevic, Lp Chp III, Mark Hirschhorn, Michael H King and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc.

Teladoc's stock was sold by a variety of institutional investors in the last quarter, including Tiger Global Management LLC, Sectoral Asset Management Inc, Elk Creek Partners LLC, Peregrine Capital Management LLC, Prudential Financial Inc., Wells Fargo & Company MN, Schroder Investment Management Group and Tiverton Asset Management LLC. Company insiders that have sold Teladoc stock in the last year include Adam C Vandervoort, Jason N Gorevic, Lp Chp III, Mark Hirschhorn, Michael H King and Trident Capital Fund Vi Lp. View Insider Buying and Selling for Teladoc.

Teladoc's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., JPMorgan Chase & Co., Jennison Associates LLC, Eagle Asset Management Inc., Riverbridge Partners LLC, Alliancebernstein L.P. and State Street Corp. View Insider Buying and Selling for Teladoc.

Shares of Teladoc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Teladoc stock can currently be purchased for approximately $31.50.